Vertex announces nav1.8 inhibitor advancing to phase 2 clinical development

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that it will advance the selective nav1.8 inhibitor, vx-548, into phase 2 clinical development with clinical trials in patients with both visceral and non-visceral types of acute pain. the decision to move to phase 2 was based on supportive phase 1 data in healthy volunteers, including safety, tolerability and pharmacokinetics (pk). in these studies, the molecule exhibited a favorable profile at doses co
VRTX Ratings Summary
VRTX Quant Ranking